Cargando…
cGAS-STING pathway in cancer biotherapy
The activation of the cGAS-STING pathway has tremendous potential to improve anti-tumor immunity by generating type I interferons. In recent decades, we have witnessed that producing dsDNA upon various stimuli is an initiative factor, triggering the cGAS-SING pathway for a defensive host. The unders...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472700/ https://www.ncbi.nlm.nih.gov/pubmed/32887628 http://dx.doi.org/10.1186/s12943-020-01247-w |
_version_ | 1783579036325249024 |
---|---|
author | Wang, Yang Luo, Jingwen Alu, Aqu Han, Xuejiao Wei, Yuquan Wei, Xiawei |
author_facet | Wang, Yang Luo, Jingwen Alu, Aqu Han, Xuejiao Wei, Yuquan Wei, Xiawei |
author_sort | Wang, Yang |
collection | PubMed |
description | The activation of the cGAS-STING pathway has tremendous potential to improve anti-tumor immunity by generating type I interferons. In recent decades, we have witnessed that producing dsDNA upon various stimuli is an initiative factor, triggering the cGAS-SING pathway for a defensive host. The understanding of both intracellular cascade reaction and the changes of molecular components gains insight into type I IFNs and adaptive immunity. Based on the immunological study, the STING-cGAS pathway is coupled to cancer biotherapy. The most challenging problem is the limited therapeutic effect. Therefore, people view 5, 6-dimethylxanthenone-4-acetic acid, cyclic dinucleotides and various derivative as cGAS-STING pathway agonists. Even so, these agonists have flaws in decreasing biotherapeutic efficacy. Subsequently, we exploited agonist delivery systems (nanocarriers, microparticles and hydrogels). The article will discuss the activation of the cGAS-STING pathway and underlying mechanisms, with an introduction of cGAS-STING agonists, related clinical trials and agonist delivery systems. |
format | Online Article Text |
id | pubmed-7472700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-74727002020-09-08 cGAS-STING pathway in cancer biotherapy Wang, Yang Luo, Jingwen Alu, Aqu Han, Xuejiao Wei, Yuquan Wei, Xiawei Mol Cancer Review The activation of the cGAS-STING pathway has tremendous potential to improve anti-tumor immunity by generating type I interferons. In recent decades, we have witnessed that producing dsDNA upon various stimuli is an initiative factor, triggering the cGAS-SING pathway for a defensive host. The understanding of both intracellular cascade reaction and the changes of molecular components gains insight into type I IFNs and adaptive immunity. Based on the immunological study, the STING-cGAS pathway is coupled to cancer biotherapy. The most challenging problem is the limited therapeutic effect. Therefore, people view 5, 6-dimethylxanthenone-4-acetic acid, cyclic dinucleotides and various derivative as cGAS-STING pathway agonists. Even so, these agonists have flaws in decreasing biotherapeutic efficacy. Subsequently, we exploited agonist delivery systems (nanocarriers, microparticles and hydrogels). The article will discuss the activation of the cGAS-STING pathway and underlying mechanisms, with an introduction of cGAS-STING agonists, related clinical trials and agonist delivery systems. BioMed Central 2020-09-04 /pmc/articles/PMC7472700/ /pubmed/32887628 http://dx.doi.org/10.1186/s12943-020-01247-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Wang, Yang Luo, Jingwen Alu, Aqu Han, Xuejiao Wei, Yuquan Wei, Xiawei cGAS-STING pathway in cancer biotherapy |
title | cGAS-STING pathway in cancer biotherapy |
title_full | cGAS-STING pathway in cancer biotherapy |
title_fullStr | cGAS-STING pathway in cancer biotherapy |
title_full_unstemmed | cGAS-STING pathway in cancer biotherapy |
title_short | cGAS-STING pathway in cancer biotherapy |
title_sort | cgas-sting pathway in cancer biotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472700/ https://www.ncbi.nlm.nih.gov/pubmed/32887628 http://dx.doi.org/10.1186/s12943-020-01247-w |
work_keys_str_mv | AT wangyang cgasstingpathwayincancerbiotherapy AT luojingwen cgasstingpathwayincancerbiotherapy AT aluaqu cgasstingpathwayincancerbiotherapy AT hanxuejiao cgasstingpathwayincancerbiotherapy AT weiyuquan cgasstingpathwayincancerbiotherapy AT weixiawei cgasstingpathwayincancerbiotherapy |